Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review
Rapamycin, an established mTOR inhibitor in clinical practice, is widely recognized for its therapeutic efficacy. Ridaforolimus, a non-prodrug rapalog, offers improved aqueous solubility, stability, and affinity compared to rapamycin. In recent years, there has been a surge in clinical trials involv...
Shranjeno v:
Main Authors: | , , , , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Frontiers Media S.A.,
2024-03-01T00:00:00Z.
|
Teme: | |
Online dostop: | Connect to this object online. |
Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Kopija 1 | Prosto |